The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
Bayer now present in four of the largest biotechnology hubs in the United States
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The second phase of the orientation workshop is being organized to provide in-depth knowledge to the state officials on core building blocks of ABDM
CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Subscribe To Our Newsletter & Stay Updated
